After Trump threatened tariffs on pharmaceutical imports, drugmakers unveiled a flurry of commitments to build or expand US manufacturing operations. But the moves aren't expected to decrease US reliance on foreign sources for key ingredients and drugs, nor are they likely to result in lower costs